SANTA MONICA, Calif. / Apr 24, 2024 / Business Wire / GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading destination for prescription savings in the U.S., today announced it will hold its first Investor Day on May 15, 2024, in New York City. The event will begin at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time).

The event will feature presentations by GoodRx’s Interim CEO, Scott Wagner; CFO, Karsten Voermann; as well as other leaders from across the Company and will include an overview of the company’s business drivers and its strategy for long-term growth, followed by a Q&A session.

A link to access the live webcast, as well as any related materials, will be available on GoodRx’s investor relations website at https://investors.goodrx.com. Following the conclusion of the event, a replay of the webcast will be available for at least 90 days.

About GoodRx

GoodRx is the leading destination for prescription savings in the U.S. We offer consumers free access to transparent and lower prices for generic and brand medications, as well as comprehensive healthcare research and information. We also equip healthcare professionals with efficient ways to find and prescribe affordable medications. Since 2011, GoodRx has helped consumers save nearly $70 billion and is one of the most downloaded medical apps over the past decade.

GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.